References
- Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001;48(4):526–535.
- Winther KV, Jess T, Langholz E, et al. Longterm risk of cancer in ulcerative colitis: a population-based cohort study from Copenhagen County. Clin Gastroenterol Hepatol. 2004;2(12):1088–1095.
- Rutter MD, Saunders BP, Wilkinson KH, et al. Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. Gastroenterology. 2006;130(4):1030–1038.
- Biancone L, Michetti P, Travis S, European Crohn's and Colitis Organisation (ECCO), et al. European evidence-based Consensus on the management of ulcerative colitis: special situations. J Crohns Colitis. 2008;2(1):63–92.
- Itzkowitz SH, Present DH, et al. Consensus conference: colorectal cancer screening and surveillance in inflammatory bowel disease. Inflamma Bowel Dis. 2005;3:314–321.
- Bernstein CN, Shanahan F, Weinstein CB. Are we telling patients the truth about surveillance colonoscopy in ulcerative colitis? Lancet. 1994;343(8889):71–74.
- Harpaz N, Polydorides AD. Colorectal dysplasia in chronic inflammatory bowel disease: pathology, clinical implications, and pathogenesis. Arch Pathol Lab Med. 2010;134(6):876–895.
- Riddel RH, Goldman H, Ransohoff DF, et al. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol. 1983;14(11):931–968.
- Van Assche G, European Crohn's and Colitis Organisation, Dignass A, Bokemeyer B, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations. J Crohns Colitis. 2013;7(1):1–33.
- Laine L, SCENIC Guideline Development Panel, Kaltenbach T, Barkun A, et al. SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease. Gastrointest Endosc. 2015;81(3):489–501.
- Galandiuk S, Justo MR, Jeffery R, et al. Field cancerization in the intestinal epithelium of patients with Crohn's ileocolitis. Gastroenterology. 2012;142(4):855–864.
- Park MMG, Loftus EV, Sandborn WJ, et al. Methylation status of genes in non-neoplastic mucosa from patients with ulcerative colitis-associated colorectal cancer. Am J Gastroenterol. 2010;105:1610–1619.
- Azuara D, Rodriguez-Moranta F, de Oca J, et al. Novel methylation panel for the early detection of neoplasia in high-risk ulcerative colitis and Crohn’s colitis patients. Inflamm Bowel Dis. 2013;19:165–173.
- Olaru AV, Cheng Y, Agarwal R, et al. Unique patterns of CpG Island methylation in inflammatory bowel disease-associated colorectal cancers. Inflamm Bowel Dis. 2012;18(4):641–648.
- Hartnett L, Egan LJ. Inflammation, DNA methylation and colitis-associated cancer. Carcinogenesis. 2012;33(4):723–731.
- Pereira C, Coelho R, Grácio D, et al. DNA damage and oxidative DNA damage in inflammatory bowel disease. ECCOJC. 2016;10(11):1316–1323.
- Van Assche G, Dignass A, Panes J, European Crohn's and Colitis Organisation (ECCO), et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis. J Crohns Colitis. 2010;4(1):7–27.
- Stange EF, Travis SPL, Vermeire S, European Crohn's and Colitis Organisation (ECCO), et al. European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis. J Crohns Colitis. 2008;2(1):1–23.
- Nygren AO, Ameziane N, Duarte HM, et al. Methylation-specific MLPA (MS-MLPA): simultaneous detection of CpG methylation and copy number changes of up to 40 sequences. Nucleic Acids Res. 2005;33(14):e128
- Schouten JP, McElgunn CJ, Waaijer R, et al. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res. 2002;30(12):e57.
- Joensuu EI, Abdel-Rahman WM, Ollikainen M, et al. Epigenetic signatures of familial cancer are characteristic of tumor type and family category. Cancer Res. 2008;68(12):4597–4605.
- Gylling A, Ridanpaa M, Vierimaa O, et al. Large genomic rearrangements and germline epimutations in Lynch syndrome. Int J Cancer. 2009;124(10):2333–2340.
- Gylling A, Abdel-Rahman WM, Juhola M, et al. Is gastric cancer part of the tumour spectrum of hereditary non-polyposis colorectal cancer? A molecular genetic study. Gut. 2007;56(7):926–933.
- Beaugerie L, Svrcek M, Seksik P, et al. Risk of colorectal high-grade dysplasia and cancer in a prospective observational cohort of patients with inflammatory bowel disease. Gastroenterology. 2013;145(1):166–175.
- Issa JP, Ahuja N, Toyota M, et al. Accelerated age-related CpG island methylation in ulcerative colitis. Cancer Res. 2001;61:3573–3577.
- Konishi K, Shen L, Wang S, et al. Rare CpG island methylator phenotype in ulcerative colitis-associated neoplasias. Gastroenterology. 2007;132(4):1254–1260.
- Sanchez JA, Dejulius KL, Bronner M, et al. Relative role of methylator and tumor suppressor pathways in ulcerative colitis-associated colon cancer. Inflamm Bowel Dis. 2011;17:1966–1970.
- Svrcek M, El-Bchiri J, Chalastanis A, et al. Specific clinical and biological features characterize inflammatory bowel disease associated colorectal cancers showing microsatellite instability. J Clin Oncol. 2007;25(27):4231–4238.
- Saito S, Kato J, Hiraoka S, et al. DNA methylation of colon mucosa in ulcerative colitis patients: correlation with inflammatory status. Inflamm Bowel Dis. 2011;17(9):1955–1965.
- Schulmann K, Mori Y, Croog V, et al. Molecular phenotype of inflammatory bowel disease-associated neoplasms with microsatellite instability. Gastroenterology. 2005;129(1):74–85.